Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters
- 1 May 1992
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 65 (5) , 751-755
- https://doi.org/10.1038/bjc.1992.158
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicinJournal of Hepatology, 1986
- How much does liver disease affect the pharmacokinetics of adriamycin?European Journal of Cancer and Clinical Oncology, 1985
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.1980
- FACILE AND DEFINITIVE DETERMINATION OF HUMAN ADRIAMYCIN AND DAUNORUBICIN METABOLITES BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY1980
- CLINICAL-PHARMACOLOGICAL EVALUATION OF HEPATIC ARTERIAL INFUSION OF ADRIAMYCIN1979
- INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICINThe Lancet, 1978
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United StatesCancer, 1977
- Treatment of hepatocellular carcinoma with adriamycin.Preliminary communicationCancer, 1975